SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001140361-23-058659
Filing Date
2023-12-20
Accepted
2023-12-20 16:31:15
Documents
13
Period of Report
2023-12-14
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A ef20017039_8ka.htm   iXBRL 8-K/A 32248
2 EXHIBIT 99.1 ef20017039_ex99-1.htm EX-99.1 327998
  Complete submission text file 0001140361-23-058659.txt   521104

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20231214.xsd EX-101.SCH 3863
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20231214_lab.xml EX-101.LAB 23291
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20231214_pre.xml EX-101.PRE 16551
7 EXTRACTED XBRL INSTANCE DOCUMENT ef20017039_8ka_htm.xml XML 4367
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

IRS No.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K/A | Act: 34 | File No.: 001-40782 | Film No.: 231501680
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)